Tradestie Institutional Equity Comparison Engine

TAK vs SNY โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SNY Overall Edge

SNY Captures Institutional Edge (2โ€“2 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Sanofi American Depositary Shares (Each representing one-half of one ordinary share) (SNY) driven by superior Valuation, Growth & Margin while TAK counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, TAK trades at 12.7x Forward P/E with 16.6% operating margin (+6.7% YoY revenue) versus SNY at 8.9x Forward P/E and 22.3% operating margin (+15.7% YoY). In options structure, TAK sits in UNCLASSIFIED (5th %ile IV; Dealer Gamma Walls on Pro) against SNY sits in UNCLASSIFIED (43rd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner SNY
TAK 12.7x vs SNY 8.9x Fwd P/E
Growth & Margin Winner SNY
Op Margin 16.6% vs 22.3% ยท YoY +6.7% vs +15.7%
Momentum & Technical Winner TAK
1Y +51.8% vs -7.4% ยท 52W Pos 97% vs 69%
Options & Structure Winner TAK
UNCLASSIFIED (5th %ile IV) vs UNCLASSIFIED (43rd %ile IV)
TAK NYSE
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Pharmaceutical Preparations
$21.61
+0.86% 1D
Market Cap $67.5B
1M Return +9.89%
1Y Return +51.79%
Forward P/E 12.7x
Unified AI Score
47.7 / 100 HOLD
Tech 42.0 Fund 43.0 Flow 50.0 Mom 40.0
SNY NASDAQ
Sanofi American Depositary Shares (Each representing one-half of one ordinary share)
Pharmaceutical Preparations
$48.47
+0.21% 1D
Market Cap $116.0B
1M Return +19.35%
1Y Return -7.39%
Forward P/E 8.9x
Unified AI Score
31.7 / 100 SELL
Tech 50.0 Fund 28.0 Flow 50.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: TAK +51.79% SNY -7.39% Spread: +59.18 pp (TAK Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
TAK TTM Op. Margin: 16.6% SNY TTM Op. Margin: 22.3%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TAK vs SNY. Trailing 12-month operating profitability (TAK 16.6% vs SNY 22.3%) and valuation multiples (TAK 12.7x vs SNY 8.9x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: TAK (3) vs SNY (7)
Institutional Metric TAK SNY Criterion Row Winner
Market Capitalization Scale $67.5B $116.0B Larger Scale SNY
Trailing P/E Ratio Valuation N/M 24.1x Lower Multiple SNY
Forward P/E Ratio Valuation 12.7x 8.9x Lower Multiple SNY
Revenue Growth (YoY) Growth +6.7% +15.7% Higher Growth SNY
Operating Margin (TTM) Profitability 16.6% 22.3% Higher Margin SNY
Net Profit Margin Profitability 0.9% 8.2% Higher Margin SNY
Return on Equity (ROE) Capital Efficiency 0.6% 5.7% Higher ROE SNY
52-Week Range Position Momentum 97% ($14โ€“$22) 69% ($39โ€“$53) Stronger Trend TAK
Beta / 30D Volatility Risk Regime -0.02ฮฒ ยท 22% Vol 0.20ฮฒ ยท 27% Vol Lower Realized Risk TAK
Unified Institutional Score Composite Signal 47.7 / 100 (HOLD) 31.7 / 100 (SELL) Higher Composite TAK

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full TAK vs SNY Buy Guide
TAK UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 5th %ile
IV Regime Compressed (<25th %ile)
Live TAK Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
SNY UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 43rd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live SNY Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither TAK nor SNY registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.